



Hiroto Inaba, MD, PhD

Member

Leukemia/Lymphoma Division, Department of Oncology

Director

Pediatric Hematology/Oncology Fellowship Program

t 901-595-3144 f 901-521-9005

E-Mail: hiroto.inaba@stjude.org

Dear WHO Expert Committee,

I am writing to express my strong support for the inclusion of **blinatumomab** on the **WHO Model List of Essential Medicines for Children (EMLc)**.

Blinatumomab has demonstrated significant clinical benefit in the treatment of **acute lymphoblastic leukemia (ALL)** in children. As a bispecific T-cell engager, it provides a targeted and effective option for patients with poor prognosis, many of whom do not respond to conventional chemotherapy. We have established **the blinatumomab humanitarian access program (BHAP)** in collaboration with manufacturer (Amgen), Direct Relief, and St. Jude Children's Research Hospital in limited number of low- and middle-income countries (LMICs). Blinatumomab is provided with free of charge for patients with high-risk B-ALL, and administration is feasible, and therapy is also shown to be effective. Its inclusion on the EMLc would be a critical step toward improving access to this innovative therapy in LMICs, where treatment options are often limited.

Including blinatumomab in the EMLc would align with the goals of the **WHO Global Initiative for Childhood Cancer (GICC)** and help reduce survival disparities by ensuring that essential, high-impact cancer medicines are made more widely available.

I respectfully urge the Committee to give this application full consideration and to support the global effort to expand access to life-saving treatment for children with cancer.

Sincerely,

Hiroto Inaba, MD, PhD